Expression of Osteopontin in the rat retina: Effects of excitotoxic and ischemic injuries

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 2, 2008, Pages 762-771

  Chidlow, Glyn ^a,b,d   Wood, John P M ^a,b   Manavis, Jim ^a   Osborne, Neville N ^c   Casson, Robert J ^a,b  

^a HANSON INSTITUTE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Hanson Centre for Neurological Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

KAINIC ACID; LIPOPOLYSACCHARIDE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID; OSTEOPONTIN; THY 1 ANTIGEN; AMINO ACID RECEPTOR STIMULATING AGENT; N METHYLASPARTIC ACID; TRANSCRIPTION FACTOR POU4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MICROGLIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REPERFUSION INJURY; RETINA DEGENERATION; RETINA GANGLION CELL; RETINA INJURY; RETINA ISCHEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; RETINA; RETINA DISEASE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, THY-1; EXCITATORY AMINO ACID AGONISTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOENZYME TECHNIQUES; KAINIC ACID; N-METHYLASPARTATE; OSTEOPONTIN; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; RETINA; RETINAL DISEASES; RETINAL GANGLION CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR BRN-3;

EID: 40649109829     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0726     Document Type: Article

References (65)

1. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43(suppl 1):S102-S128.
2. Louzada Junior P, Dias JJ, Santos WF, Lachat JJ, Bradford HF, Coutinho Netto J. Glutamate release in experimental ischaemia of the retina: an approach using microdialysis. J Neurochem. 1992;59:358-363.
3. Yoles E, Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol. 1998;116:906-910.
4. Brandstatter JH, Hartveit E, Sassoe Pognetto M, Wassle H. Expression of NMDA and high-affinity kainate receptor subunit mRNAs in the adult rat retina. Eur J Neurosci. 1994;6:1100-1112.
5. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells: toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37:1618-1624.
6. Vorwerk CK, Kreutz MR, Bockers TM, Brosz M, Dreyer EB, Sabel BA. Susceptibility of retinal ganglion cells to excitotoxicity depends on soma size and retinal eccentricity. Curr Eye Res. 1999;19:59-65.
7. Chidlow G, Osborne NN. Rat retinal ganglion cell loss caused by kainate, NMDA and ischemia correlates with a reduction in mRNA and protein of Thy-1 and neurofilament light. Brain Res. 2003;963:298-306.
8. Yoles E, Muller S, Schwartz M. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J Neurotrauma. 1997;14:665-675.
9. Weber M, Bonaventure N, Sahel JA. Protective role of excitatory amino acid antagonists in experimental retinal ischemia. Graefes Arch Clin Exp Ophthalmol. 1995;233:360-365.
10. Lam TT, Siew E, Chu R, Tso MO. Ameliorative effect of MK-801 on retinal ischemia. J Ocul Pharmacol Ther. 1997;13:129-137.
11. Nickells RW. The molecular biology of retinal ganglion cell death: caveats and controversies. Brain Res Bull. 2004;62:439-446.
12. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms ofdamage and potential therapeutic strategies. Prog Retin Eye Res. 2004;23:91-147.
13. Denhardt DT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol. 2001;41:723-749.
14. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin: a molecule for all seasons. Q J Med. 2002;95:3-13.
15. Chakraborty G, Jain S, Behera R, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med. 2006;6:819-830.
16. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006;16:79-87.
17. Iczkiewicz J, Rose S, Jenner P. Osteopontin (Eta-1) is present in the rat basal ganglia. Brain Res Mol Brain Res. 2004;132:64-72.
18. Lee MY, Choi JS, Lim SW, Cha JH, Chun MH, Chung JW. Expression of osteopontin mRNA in developing rat brainstem and cerebellum. Cell Tissue Res. 2001;306:179-185.
19. Shin SL, Cha JH, Chun MH, Chung JW, Lee MY. Expression of osteopontin mRNA in the adult rat brain. Neurosci Lett. 1999;273:73-76.
20. Schroeter M, Zickler P, Denhardt DT, Hartung HP, Jander S. Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice. Brain. 2006;129:1426-1437.
21. Wang X, Louden C, Yue TL, et al. Delayed expression of osteopontin after focal stroke in the rat. J Neurosci. 1998;18:2075-2083.
22. Ellison JA, Velier JJ, Spera P, et al. Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke. 1998;29:1698-1706.
23. Lee MY, Shin SL, Choi YS, et al. Transient upregulation of osteopontin mRNA in hippocampus and striatum following global forebrain ischemia in rats. Neurosci Lett. 1999;271:81-84.
24. Kim SY, Choi YS, Choi JS, et al. Osteopontin in kainic acid-induced microglial reactions in the rat brain. Mol Cells. 2002;13:429-435.
25. Meller R, Stevens SL, Minami M, et al. Neuroprotection by osteopontin in stroke. J Cereb Blood Flow Metab. 2005;25:217-225.
26. Hikita ST, Cann GM, Wingerd KL, et al. Integrin alpha4beta1 (VLA-4) expression and activity in retinal and peripheral neurons. Mol Cell Neurosci. 2003;23:427-439.
27. Ju WK, Kim KY, Cha JH, et al. Ganglion cells of the rat retina show osteopontin-like immunoreactivity. Brain Res. 2000;852:217-220.
28. Hikita ST, Vistica BP, Jones HR, et al. Osteopontin is proinflammatory in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2006;47:4435-4443.
29. Weishaupt JH, Klocker N, Bahr M. Axotomy-induced early down-regulation of POU-IV class transcription factors Brn-3a and Brn-3b in retinal ganglion cells. J Mol Neurosci. 2005;26:17-25.
30. Marini F, Pozzato C, Andreetta V, et al. Single exposure to social defeat increases corticotropin-releasing factor and glucocorticoid receptor mRNA expression in rat hippocampus. Brain Res. 2006;1067:25-35.
31. Chidlow G, Casson R, Sobrado-Calvo P, Vidal-Sanz M, Osborne NN. Measurement of retinal injury in the rat after optic nerve transection: an RT-PCR study. Mol Vis. 2005;11:387-396.
32. Schlamp CL, Johnson EC, Li Y, Morrison JC, Nickells RW. Changes in Thy1 gene expression associated with damaged retinal ganglion cells. Mol Vis. 2001;7:192-201.
33. Fu Y, Hashimoto M, Ino H, Murakami M, Yamazaki M, Moriya H. Spinal root avulsion-induced upregulation of osteopontin expression in the adult rat spinal cord. Acta Neuropathol. 2004;107:8-16.
34. Shin T, Ahn M, Kim H, et al. Temporal expression of osteopontin and CD44 in rat brains with experimental cryolesions. Brain Res. 2005;1041:95-101.
35. Hashimoto M, Koda M, Ino H, Murakami M, Yamazaki M, Moriya H. Upregulation of osteopontin expression in rat spinal cord microglia after traumatic injury. J Neurotrauma. 2003;20:287-296.
36. Choi JS, Park HJ, Cha JH, Chung JW, Chun MH, Lee MY. Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J Neuroimmunol. 2003;141:65-73.
37. Iczkiewicz J, Rose S, Jenner P. Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat. Eur J Neurosci. 2005;21:1911-1920.
38. von Gertten C, Flores Morales A, Holmin S, Mathiesen T, Nordqvist AC. Genomic responses in rat cerebral cortex after traumatic brain injury. BMC Neurosci. 2005;6:69.
39. Siliprandi R, Canella R, Carmignoto G, et al. N-methyl-D-aspartateinduced neurotoxicity in the adult rat retina. Vis Neurosci. 1992;8:567-573.
40. Rao NA, Kimoto T, Zamir E, et al. Pathogenic role of retinal microglia in experimental uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:22-31.
41. Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol. 2004;75:388-397.
42. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735.
43. Moon C, Shin T. Increased expression of osteopontin in the spinal cords of Lewis rats with experimental autoimmune neuritis. J Vet Sci. 2004;5:289-293.
44. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol. 2005;31:292-303.
45. Petrow PK, Hummel KM, Schedel J, et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 2000;43:1597-1605.
46. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2007;8:74-83.
47. Xu G, Nie H, Li N, et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest. 2005;115:1060-1067.
48. Zohar R, Zhu B, Liu P, Sodek J, McCulloch CA. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway. Am J Physiol. 2004;287:H1730-H1739.
49. Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR, Walther SE. Osteopontin-induced modifications of cellular functions. Ann NY Acad Sci. 1995;760:127-142.
50. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem. 2002;85:728-736.
51. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276:46024-46030.
52. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959-20962.
53. Noiri E, Dickman K, Miller F, et al. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int. 1999;56:74-82.
54. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int. 1999;56:571-580.
55. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell. 2004;15:2834-2841.
56. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol. 1998;141:1083-1093.
57. Guo H, Cai CQ, Schroeder RA, Kuo PC. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macro-phages. J Immunol. 2001;166:1079-1086.
58. Rollo EE, Laskin DL, Denhardt DT. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macro-phages. J Leukoc Biol. 1996;60:397-404.
59. Tian JY, Sorensen ES, Butler WT, et al. Regulation of no synthesis induced by inflammatory mediators in RAW264.7 cells: collagen prevents inhibition by osteopontin. Cytokine. 2000;12:450-457.
60. Wai PY, Guo L, Gao C, Mi Z, Guo H, Kuo PC. Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery. 2006;140:132-140.
61. Neufeld AH, Kawai S, Das S, et al. Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase. Exp Eye Res. 2002;75:521-528.
62. Hangai M, Yoshimura N, Hiroi K, Mandai M, Honda Y. Inducible nitric oxide synthase in retinal ischemia-reperfusion injury. Exp Eye Res. 1996;63:501-509.
63. Arafat HA, Katakam AK, Chipitsyna G, et al. Osteopontin protects the islets and β-cells from interleukin-1 β-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology. 2007;148:575-584.
64. Attur MG, Dave MN, Stuchin S, et al. Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum. 2001;44:578-584.
65. Yoneda S, Tanihara H, Kido N, et al. Interleukin-1beta mediates ischemic injury in the rat retina. Exp Eye Res. 2001;73:661-667.